Clinical Significance of High-Sensitivity Cardiac Troponin T in Patients With Dilated Cardiomyopathy

  • Baba Yuichi
    Department of Cardiology, Neurology and Aging Science, Kochi Medical School
  • Kubo Toru
    Department of Cardiology, Neurology and Aging Science, Kochi Medical School
  • Yamanaka Shigeo
    Department of Laboratory Medicine, Kochi Medical School
  • Hirota Takayoshi
    Department of Cardiology, Neurology and Aging Science, Kochi Medical School
  • Tanioka Katsutoshi
    Department of Cardiology, Neurology and Aging Science, Kochi Medical School
  • Yamasaki Naohito
    Department of Cardiology, Neurology and Aging Science, Kochi Medical School
  • Sugiura Tetsuro
    Department of Laboratory Medicine, Kochi Medical School
  • Kitaoka Hiroaki
    Department of Cardiology, Neurology and Aging Science, Kochi Medical School

この論文をさがす

抄録

Although conventional cardiac troponin T (cTnT) and I (cTnI) markers have been reported to predict adverse outcome in dilated cardiomyopathy (DCM), the usefulness of a new-generation high-sensitivity assay of cardiac troponin T (hs-cTnT) compared with these conventional biomarkers is unclear.<br>We performed clinical evaluation including measurements of troponin markers in 54 patients with DCM under a clinically stable condition. At baseline, the serum concentration of hs-cTnT was 0.014 ± 0.016 ng/mL and 17 (31%) of the patients showed abnormal hs-cTnT values (> 0.014 ng/mL). During a mean follow-up period of 5.1 ± 1.6 years, there were 16 cardiac events: heart failure death in 6 patients, sudden cardiac death in 2 patients, and hospitalization for heart failure in 8 patients. Patients with abnormal hs-cTnT or abnormal cTnT (> 0.01 ng/mL) values had significantly more frequent cardiac events than did those with normal hs-cTnT or cTnT values. On the other hand, abnormal cTnI (> 0.03 ng/mL) value did not reach statistical significance for these adverse events. Multivariate analysis showed that only an abnormal hs-cTnT value was an independent predictor of all cardiac events (HR: 5.68, P = 0.003). When the patients were divided into 4 groups according to the degree of hs-cTnT levels, the clinical course was significantly worse in patients with higher hs-cTnT values.<br>These results suggest that the serum concentration of hs-cTnT provides better risk stratification in DCM patients.

収録刊行物

  • International Heart Journal

    International Heart Journal 56 (3), 309-313, 2015

    一般社団法人 インターナショナル・ハート・ジャーナル刊行会

被引用文献 (5)*注記

もっと見る

参考文献 (24)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ